← All trials
NCT05093478
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 10, 2019
- Primary completion
- Jun 30, 2022
- Completion date
- Jun 30, 2022
- First posted
- Oct 26, 2021
- Last posted
- Oct 26, 2021
- Enrollment
- 33
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Texas at HoustonLead sponsor
- University of Texas at HoustonReponsible party - principal investigator
- University of Texas at HoustonOverall official - principal investigator
- American Academy of Otolaryngic AllergyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.